Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Functional Analysis of Epidermal Growth Factor Receptor (EGFR) Mutations and Potential Implications for EGFR Targeted Therapy
Ist Teil von
Clinical cancer research, 2009-01, Vol.15 (2), p.460-467
Ort / Verlag
Philadelphia, PA: American Association for Cancer Research
Erscheinungsjahr
2009
Link zum Volltext
Quelle
Elektronische Zeitschriftenbibliothek
Beschreibungen/Notizen
Purpose: Epidermal growth factor receptor (EGFR) mutations in non–small cell lung cancer (NSCLC) might be predictive for clinical
response to EGFR inhibitor treatment. However, retrospective analyses of EGFR mutations in clinical trials have shown inconclusive
results and the effect of EGFR sequencing in NSCLC is still controversial. Because the vast majority of EGFR mutations described
have not been functionally characterized, simple correlation of mutational status and treatment response may not provide reliable
information about the predictive value of EGFR mutations. Thus, we aimed to characterize a comprehensive panel of clinically
observed EGFR mutations.
Experimental Design and Results: A panel of 30 EGFR mutations was cloned and characterized for kinase activity and the ability to confer growth factor independence.
Interestingly, 4 of 30 EGFR mutations showed no kinase activity even after ligand stimulation and were not able to confer
growth factor independence. Ba/F3 cells expressing activating EGFR mutants were then used to test the efficacy of EGFR inhibitors
in a cell proliferation assay. IC 50 values were calculated for gefitinib, erlotinib, and AEE788. We show that the sensitivity of EGFR mutations toward different
inhibitors varies significantly, thus establishing a comprehensive sensitivity profile for each inhibitor.
Conclusions: EGFR mutations identified in NSCLC patients display distinct biological features. The variability in kinase activity, transforming
potential, and sensitivity to EGFR inhibitors has to be considered in clinical studies aiming to correlate mutational status
and drug response. The identification of comprehensive drug resistance profiles opens the opportunity to test alternative
EGFR inhibitors in vitro .